scholarly journals Conservative Management of Idiopathic Hemophagocytic Lymphohistiocytosis (HLH) Achieving Complete Remission

Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 4963-4963
Author(s):  
Jesus C Fabregas ◽  
Guiset Carvajal

Abstract Introduction Hemophagocytic lymphohistiocytosis (HLH) is a syndrome characterized by overwhelming activation of the immune system. The disease can affect patients of all ages and many times it goes under recognized for long periods of time, thus increasing its mortality due to organ failure. It mainly affects infants, nonetheless, adults can suffer from the disease as well, with catastrophic consequences. HLH etiology subsumes sporadic and familial presentations. Of the former, the two more common causes are infectious and neoplastic conditions. Clinical presentation includes nonspecific findings such as jaundice, hepatosplenomegaly, fever, fatigue, neurologic deficits. Laboratory findings display a spectrum of cytopenias, hemolysis, elevated ferritin, elevated IL-2, hypertriglyceridemia. Early initiation of treatment accounts for a great deal of the patient's recovery. Treatment consists of immunosuppressive therapy such as the HLH94 protocol - includes etoposide and dexamethasone -, or other combination immunosuppressive regimens. Using steroids alone is not typically a standard approach for the management of patients with HLH. Here we present a case of a patient with HLH with likely infectious etiology, successfully treated with steroids alone. Case Presentation A 34-year-old male patient presented to the emergency room (ER) complaining of jaundice, abdominal distention, fatigue, weakness, and fevers to 102 F. Vital signs were stable except for tachycardia hear rate 119 /min. Physical exam disclosed the presence of hepatosplenomegaly, palpable edge of liver, spleen palpable 6 cm below left costal margin, skin with jaundice. Blood work showed signs of cytopenias and hemolysis. WBC 2.2 /uL, hemoglobin 6.1 gr/dL, platelet count 114,000 /uL, neutrophil percentage 35%. On his peripheral smear review he had excessive monocytosis of 18%, atypical lymphocytes 31%, and 4% basophils. Reticulocyte count 1.3%. INR 1.2. AST elevated at 305 U/L, ALT 230 U/L, LDH 1063 U/L, Albumin 3.0 , total bilirubin 25.9, direct bilirubin 19.69, sodium 129. Haptoglobin less than 8. Coombs direct positive IgG subtype. Differential diagnosis included warm autoimmune hemolytic anemia. CT scan of the abdomen with contrast showed splenomegaly, 19.4 cm coronal view (fig 1), hepatomegaly as well, 21 cm in the mid hepatic craniocaudal diameter, steatosis. The patient was started on prednisone 1 mg/kg with rapid improvement on his laboratory parameters within the first 48 hours. A ferritin level on the third day of hospitalization was elevated at 2184. This finding along with unexplained transaminitis and hepatosplenomegaly raised suspicion for HLH. The patient met 6 out of the 8 criteria for diagnosis: Cytopenias (nadir ANC less than 1000, thrombocytopenia nadir 112,000, anemia), fever, splenomegaly, soluble CD25 (IL-2) elevated at 1803 pg/mL (normal values less than 1033 pg/mL), triglycerides 309 mg/dL, ferritin level 2184. Thus, the following workup was conducted. A. Bone marrow aspiration and biopsy showed hypercellular marrow with erythroid hyperplasia, negative for lymphoma or leukemia, adequate trilineage hematopoiesis (fig 2). B. Flow cytometry from peripheral blood was negative for paroxysmal nocturnal hemoglobinuria. C. PET-CT scan done negative for malignancy. D. Brain MRI: normal. E. Extensive infectious workup: the patient was found to have positive PCR, less than 2000 copies/mL, for Epstein-Barr virus. E. HLH gene panel was sent out showing negative results. F. Liver biopsy demonstrated extramedullary hematopoiesis. G. Reduced natural killer T cell cytotoxicity; reduced perforin levels. The patients' hemolysis, cytopenias and hepatosplenomegaly rapidly improve after initiation of steroids. The patient continued on steroid regimen during 6 months on a taper. Conclusion HLH is a devastating disease that potentially culminates in multisystem organ failure if not appropriately treated. At the time of clinical suspicion of HLH, approximately 3 days after the patient's admission, his clinical condition had improved on high dose steroids alone, therefore additional immunosuppression was not initiated. The patient might have had EBV that precipitated his HLH, however at the time of diagnosis his viral load was less than 2000 copies/mL and antiviral therapy was not considered necessary. He continues to be in remission, asymptomatic, 9 months after original diagnosis. Figure. Figure. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2019 ◽  
Vol 134 (Supplement_1) ◽  
pp. 5341-5341
Author(s):  
Yue Song ◽  
Yini Wang ◽  
Jingshi Wang ◽  
Zhao Wang

Background: Hemophagocytic lymphohistiocytosis (HLH) is a severe or even fatal inflammatory status caused by a hereditary or acquired immunoregulatory abnormality. It is divided into two categories: primary and secondary. Secondary HLH (sHLH) is often associated with and caused by infections, malignant tumors, and autoimmune diseases. Lymphoma associated HLH (LAHS) is one of the most common sHLH, usually presents worse prognosis higher mortality. The treatment strategy for LAHS is still controversial. Etoposide is one of the key drug in HLH-94/04 regimen. We sought to identify the importance of including etoposide in the initial treatment of LAHS, especially comparing with the high dose chemotherapy. Methods: The patients diagnosed as LAHS in our center between Jan 1 2015 and Dec 31 2017 were observed. Survival times were calculated from the date of diagnosis of HLH. All patients were followed up until death or 31 Dec 2018, whichever occurred first. Patients undergoing stem cell transplantation were censored on the date of that procedure. Results: There were 68 patients in total. The median age of the patients was 48 years (15-76 years). They were divided into two groups according to weather the initial treatment containing etoposide. There were 53 patients with initial etoposide and 15 without it. The baseline level between two group shows no differences (p>0.05). The treatment regimens with initial etoposide include HLH-94/04 regimen, DEP (doxorubicin-etoposide-methylprednisolone), L-DEP (PEG-aspargase and DEP regimen), E-CHOP (etoposide and CHOP regimen) and RE-CHOP; those without the initial etoposide, but high-dose chemotherapy, include CHOP/COP, R-CHOP/COP, L-CHOP, CVAD, L-GDP regimen and et al. The response rates of the 68 patients was 66.1%, with the CR rate of 25% (17/68) and PR rate of 41.1% (28/68). A total of 32 cases with initial etoposide achieved remission, and the remission rate was 71.7% (CR 28.3% and PR 43.4%). 7 cases with chemotherapy without etoposide achieved remission, and the remission rate was 46.7%. A significant difference was noted between the two groups (p<0.01). A total of 41 deaths occurred with a total mortality rate of 60.3%. There were 28 deaths in patients with initial etoposide (mortality rate 52.8%) and 13 deaths in the other group (mortality rate 86.6%). A significant difference in mortality was noted between the two groups (p=0.020). Comparing the long-time survival between two groups, the survival of the initial etoposide group (101w±13, 95%CI [76, 127]) is significantly better than that of the no initial etoposide group(37w±12.7, 95% CI [12.0, 61.9]) (p=0.43) (Figure 1). Conclusion: As one of the secondary HLHs, LAHS suffers the worst outcome among all the types of HLH. This study found that initial treatment including etoposide, comparing with the chemotherapy without etoposide, can provide higher response rate, lower mortality rate and better survival. Figure 1 Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4102-4102
Author(s):  
Yasuhiro Okamoto ◽  
Yoshihisa Nagatoshi ◽  
Akinobu Matsuzaki ◽  
Aiko Suminoe ◽  
Hideki Nakayama ◽  
...  

Abstract Abstract 4102 Background Previously we reported the result of Kyushu-Yamaguchi Children's Cancer Study Group (KYCCSG) protocol, ALL-96, for pediatric acute lymphoblastic leukemia (ALL) (ASH meeting in 2005). The 7-year event-free survival (EFS) and overall survival (OS) rates were 72% (95% CI; 68 - 76 %) and 85 % (95% CI; 80 - 90 %), respectively. Following protocol, ALL-02, was aimed to assess the usefulness of polymerase chain reaction (PCR)-based minimal residual disease (MRD) in the same context as ALL-96 protocol. Purpose In this combined analysis, we analyzed the outcome and risk factors for relapse/survival in children with T-ALL who were treated with the ALL-96/ALL-02 protocols. Study Design and Treatment A total of 42 patients (22 of 218 in ALL-96 and 20 of 165 in ALL-02, 26 males and 16 females) with median age of 8 years (range 1 - 14) were treated. Patients were classified into 2 groups, standard risk (SR) and high risk (HR). HR patients had one of the followings: high white blood cell (WBC) counts more than 50,000/μl, T-cell immunophenotype, central nervous system (CNS) disease at diagnosis, organomegaly (hepatomegaly or splenomegaly more than 5 cm below costal margin), M2/3 marrow at day 15 of induction therapy. Both protocols consisted of induction, early intensification, consolidation, late intensification and maintenance therapy. Predonisolone (PSL), weekly vincristine (VCR), 4 doses of daunorubicin (DNR), 8 doses of L-asparaginase (L-asp) and 2 or 4 doses of intrathecal (IT) methotrexate (MTX) depending on the CNS status, were given during induction. In early intensification, DNR, cytarabine (CA), etoposide and 6-mercaptopurine (6-MP) were given. Consolidation consisted of intermediate dose of MTX, combination of cyclophosphamide(CPM), CA and 6-MP, and high dose CA. Late intensification similar to induction included 2 weeks of dexamethasone (DEX), weekly VCR, 2 doses of pirarubicin, single dose of CPM, 5 doses of L-asp and IT-MTX followed by combination of CA, 6-MP, IT-MTX along with 18 Gy cranial irradiation in 12 fractions. In ALL-96 protocol, patients were randomized to receive maintenance therapy of either combination of 6-MP/MTX and DEX/ VCR pulse (A-arm) or LSA2L2-type therapy (B-arm). In ALL-02 protocol, A-arm was chosen as a maintenance therapy based on result of ALL-96. No patient underwent hematopoietic stem cell transplantation (SCT) in 1st complete remission (CR). Results Median follow-up periods were 96 and 38 months in ALL-96 and ALL-02, respectively. Two patients were off-protocol before achieving CR because of toxicity and chromosome abnormality with t(4;11). Induction rate in 40 patients was 95%. All 14 events were relapses and TRM rate was 0%. Last event occurred at 40 months. The sites of relapse were isolated BM in 9, isolated testis in 2, isolated CNS in 1 and combined sites in 2. Nine died from disease progression and 2 died from toxicity after SCT in 2nd CR. The 4-year EFS and OS rates in all patients were 55 % (95 % CI; 39 – 71 %) and 71 % (95 % CI; 56 -86 %), respectively. EFS of ALL-96 and ALL-02 were 50 %[95 % CI; 29 -71 %]) and 65 % [95 % CI; 45 - 85 %]), respectively. OS of ALL-96 and ALL-02 were 59 % [95 % CI; 39 – 80 %]) and 90 % [95 % CI; 77 - 103 %]), respectively (p = 0.063). EFS of patients treated in A and B arm were 60 % [95 % CI; 41 -71 %]) and 55 % [95 % CI; 25 - 84 %]), respectively. None of age, sex, organomagaly, WBC, chromosomal abnormalities, CNS status, protocol, and maintenance arm was identified as a risk factor for relapse or survival. Two of 10 (ALL-96) and 3 of 4 (ALL-02) relapsed patients have survived with allogeneic SCT. Conclusion Although T-ALL patients received an intensified treatment including cranial radiation, the outcome was unsatisfactory. One possible explanation for better OS in ALL-02 protocol is that the majority of relapsed patients in ALL-02 were salvaged by SCT in 2nd CR. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 4686-4686
Author(s):  
Suparna Ajit Rao ◽  
Tarun K. Dutta ◽  
Rakesh V Naik ◽  
Aishwarya Krishnamurthy ◽  
Vinod K. Viswanath

Abstract Abstract 4686 A 38 year old woman presented with high grade fever and jaundice for one month. Patient also had reduced appetite and loss of weight for the same period. On examination, patient had significant pallor, icterus and pedal edema. Ultrasonogram showed enlarged liver (20 cms) and enlarged spleen (17.2 cms). Patient was empirically treated for malaria. Her subsequent investigations revealed Hb 35g/dl, total leucocyte count 2×109/l, differential leucocyte count - neutro 82%, lympho 18%, platelet count − 59×109/l, and red cell indices were as follows: MCV 71.6 fL, MCH 21.6 pg/cell, MCHC 30.2 g/dl. Her reticulocyte count was 0.5%. Peripheral blood smear showed pancytopenia with moderate anisopoikilocytosis. Her total bilirubin was 4.2 mg/dl and serum ferritin was found to be 1720 μg/L. In view of pancytopenia and non-response to antimalarials, patient was treated in line of septicemia with piperacillin and tazobactam, and simultaneously a bone marrow biopsy was performed. Bone marrow biopsy subsequently revealed a hypercellular marrow with erythroid hyperplasia. Number of macrophages was increased with some showing ingested red cells (hemophagocytosis) within them. In view of fever, splenomegaly, pancytopenia, hemophagocytosis and hyperferritinemia, a diagnosis of hemophagocytic lymphohistiocytosis (HLH) was made as per HLH 2004 diagnostic criteria. Bone marrow also revealed multifocal epithelial granulomas with caseation, pointing the etiology to that of disseminated tuberculosis. Patient expired before any anti-tuberculous treatment could be instituted. Causes of HLH are broadly malignancy, collagen diseases and infections. Though malignancy and collagen diseases are common causes in the Western countries, tuberculosis is an important cause in a tropical country like India. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2013 ◽  
Vol 122 (21) ◽  
pp. 4829-4829
Author(s):  
Moussab Damlaj ◽  
Chantal Séguin

Background warm auto-immune hemolytic anemia (AIHA) results from targeted antibodies towards the RBCs and can be secondary to certain diseases (auto-immune disease or malignancy), drugs, infections or may be idiopathic in nature. Patients with DiGeorge syndrome are vulnerable to auto-immune conditions secondary to thymic hypoplasia with an estimated incidence in one series of 8.5% (Tison, Nicholas et al. 2011). First line therapy of AIHA consists of corticosteroids with an anticipated response rate of 80% (Lechner and Jager 2010). Relapses are not uncommon and are treated with splenectomy or rituximab. Case we describe an unusual case of an 18 year old female with DiGeorge syndrome who presented with AIHA refractory to usual modes of therapy. In this case, she was diagnosed with immune thrombocytopenia purpura (ITP) at age 13 with multiple relapses following successful standard therapy. Eventually, she was managed with monthly IVIG (intravenous immune globulin) infusions and thrombopoietin analogue romiplostim, maintaining her platelet count between 50 - 100 x 10 9/L. At 18 years of age she presented with severe anemia (Hb 55 g/L), positive hemolytic markers and a positive direct Coombs (3+ IgG and negative C3). A diagnosis of AIHA was established, and patient was started on prednisone (1-1.5 mg/kg) with transfusion support. Due to lack of response, high dose IVIG was administered followed by weekly rituximab 375 mg/m2. Due to hemodynamic instability, Rituximab was interrupted after the second dose. The finding of ineffective erythropoiesis evident by inappropriately low reticulocytosis prompted a bone marrow aspirate and biopsy. Aside from erythroid hyperplasia (M:E ratio of 1:4) with a left shift, no other anomaly was noted. PNH and G6PD screen was negative. The refractory nature of her AIHA required that the patient undergo a splenectomy. Hemolytic markers transiently improved however, within a few days, her hemolytic picture worsened and patient remained transfusion dependent. Given deterioration of her clinical status, decision was made to proceed with plasma exchange (PE) daily for 5 sessions with fresh frozen plasma fluid replacement. 24 hours following her first exchange session, there was a steady improvement of her hemolytic markers and patient became transfusion independent (Fig 1). Hb normalized eight days following the last exchange session. Additionally, platelets normalized following the splenectomy and she no longer required romiplostim. At her last follow up, 280 days following her last session of PE, Her Hb is within normal limits and hemolytic markers continue to be negative. During her admission, she required 42 bags of PRBCs (Fig 2). Conclusion This is the first reported case of a DiGeorge syndrome presenting with refractory AIHA successfully treated with PE. We conclude in this case that the combination of splenectomy followed by PE successfully controlled her hemolysis. Thus, we hope this report will give an additional insight on the use of PE as a therapeutic modality in refractory cases. Disclosures: No relevant conflicts of interest to declare.


Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 4889-4889 ◽  
Author(s):  
Qiguo Zhang ◽  
Hui Zeng ◽  
Peipei Xu ◽  
Jing Wang ◽  
Ronggong Yang ◽  
...  

Abstract Objective: To increase the knowledge and experience of treating left-sided endocarditis patients complicated with hemophagocytic lymphohistiocytosis. Method: One case with left-sided endocarditis and secondary hemophagocytic lymphohistiocytosis was reported and related PubMed literatures were reviewed. Results: A 40-year-old Asian female came to hospital with uncontrolled repeated fever that had lasted for more than one month. Prior to this admission, the patient suffered a sub-acute liver failure of unknown cause and received artificial liver support and intravenous hepatic protectants in the local hospital, and the patient responded well. At that time echocardiography revealed congenital heart disease. After admission to our hospital, her lab results showed pancytopenia, coagulation abnormal and significantly elevated levels of total bilirubin, soluble CD25 and serum ferritin. Bone marrow biopsy was negative for hemaphagocytosis. The full body PET-CT was performed and the results demonstrated hepato-splenomegaly and relatively increased standard uptake value (SUV) of the spleen, with no signs of malignancies. Several sets of blood cultures were all positive for methicillin-resistant Staphylococcus epidermidis (MRSE). Two weeks later, cardiac ultrasound images were obtained and showed a completely well-shaped vegetation attached to the aorta valve, which confirmed the diagnosis of definite infectious endocarditis (IE). So the final diagnosis was the MRSE-related left-sited infectious endocarditis and acquired HLH. The Multi-disciplinary team (MDT) discussed this critical case, since the allergic reaction of vancomycin and no therapeutic effect of tecolplanin for 10 days, the patient was treated by high dose daptomycin(10 mg/kg once daily) and chemotherapy according to HLH-2004 protocol, afterwards the patient's condition was improved, cardiothoracic surgery was performed smoothly and the vegetation on the aortic valve was successfully removed. Till now the patient has been in good condition for more than 2 years. There are only 4 case reports pertinent to endocarditis with HLH published in PubMed and these related cases were also reviewed. Conclusion: This case report is the description of another rare and complicated condition in which the patient concurrently developed left-sided infectious endocarditis and acquired HLH. High dose daptomycin monotherapy was effective for controlling MRSE-related left-sided IE. Early diagnosis and intervention is very important for the successful treatment of HLH. Our case also highlights the importance of the multi-disciplinary team (MDT) model in dealing with similar critical cases in the clinic work. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2014 ◽  
Vol 124 (21) ◽  
pp. 2748-2748 ◽  
Author(s):  
Yini Wang ◽  
Zhao Wang ◽  
Wenqiu Huang ◽  
Liangding Hu ◽  
Xinan Cen ◽  
...  

Abstract Purpose: Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening hyperinflammatory syndrome. Current standard therapy increased the complete remission (CR) rate to more than 50%. Even so, about 30% patients fail the standard treatment. This study aimed to investigate the efficacy of liposomal doxorubicin together with etoposide, and high dose methylprednisolone (DEP) as a salvage therapy for adult refractory HLH. Methods: Refractory HLH was defined as patient who did not achieve at least partial remission (PR) 2 weeks after initial standard HLH therapy. The DEP regimen included liposomal doxorubicin 25mg/m2 d1, etoposide 100mg/m2 Qw and methylprednisolone 15mg/kg d1-3, 2mg/kg d4-6, 1mg/kg d7-10,0.75mg/kg d11-14. We estimated the curative effect after 2 weeks therapy and 4 weeks therapy. Results: We observed 63 refractory HLH patients from Jun 2013 to Jun 2014, including 42 males and 21 females. All the data were gathered from Beijing Friendship Hospital, 307 Hospital of PLA, Peking University People’s Hospital, Peking University Third Hospital, Beijing Chao-Yang Hospital, and Navy General Hospital. The median age was 34 years old (Range 18-78). Seventeen patients (27.0%) achieved CR and 31 patients (49.2%) achieved PR. The overall response reached 76.2% (48/63). The underlying disease of HLH were diagnosed within 2 to 8 weeks after HLH diagnosis, including 29 cases of lymphoma associated HLH, 22 cases of EBV associated HLH and 4 cases of familial HLH. There were still 8 cases had unknown underlying disease. The patients who had no response to DEP were died within 2 to 4 weeks after salvage therapy. Twenty-nine of the 48 patients who achieved PR or CR survived to undergo subsequent chemotherapy, allogenic hematopoietic stem cell transplantation (allo-HCT) or splenectomy. There were significant improvements on leukocytes, ferritin and soluble CD25 (sCD25) after 2 weeks therapy. Thrombocytes and glutamic-pyruvic transaminase (GPT) had improvements after 4 weeks therapy. Conclusion: DEP regimen appears to be an effective salvage protocol for refractory HLH. Prospective randomized controlled trials of DEP regimen will further estimated the curative effect and define optimal dosing levels and schedules. Disclosures No relevant conflicts of interest to declare.


2019 ◽  
Author(s):  
Jingcheng Li ◽  
Kai Chang ◽  
Lili Zhang ◽  
Yan Pi

Abstract Background We present the first case of Anti-IgLON5 disease with unremarkable or unspecific brain magnetic resonance imagings, and poor responsiveness to immunotherapy.Case presentation A 37-year-old man presented with 4-day history of gait instability, dysarthria, and oculomotor abnormalities. The initial neurologic examination revealed mild unsteady gait, subtle dysarthria, and left abducent paralysis. The brain MRI imaging showed multiple, scattered diffusion restriction in the bilateral cerebral hemispheres involving left tegmentum of the midbrain, and occipital horn of right lateral ventricle, without contrast enhancement. The Anti-IgLON5 antibodies were detected in the serum (titer 1:32). Furthermore, the human leukocyte antigen (HLA) genotyping confirmed HLA-DRB1*11:01 and HLA-DRB1*15:01, HLA-DQB1*03:01 and HLA-DQB1*06:02 alleles. The symptoms of patient rapid improvement after high-dose intravenous methylprednisolone and immunoglobulins.Conclusions In this paper, we report a new case of anti-IgLON5 disease with major symptoms of gait instability, dysarthria, and oculomotor abnormalities, with distinctive brain magnetic resonance findings, and responsive to immunotherapy.


2020 ◽  
Author(s):  
THOMAS FOIADELLI ◽  
CHIARA TRABATTI ◽  
FRANCESCO BASSANESE ◽  
ENRICO LANDI ◽  
AMELIA LICARI ◽  
...  

Abstract Background: Acute disseminated encephalomyelitis (ADEM) is an inflammatory demyelinating disorder of the central nervous system (CNS), whose pathogenesis is still debated. It occurs more frequently in children, and the first neurological symptoms usually appear between 2 and 4 weeks after a trigger event, such as an infection or vaccination. Several viral agents have been related to the development of ADEM, while bacteria and parasites are less frequently involved. Severe Streptococcus pneumoniae infection has been rarely described as a trigger for CNS demyelination in particularly predisposed subjects.Case presentation: A 10 year old girl was evaluated for headache, fever and vomit. CSF analysis revealed pleocytosis and presence of S. pneumoniae antigen, and proper antibiotic therapy for bacterial meningitis was started, with rapid improvement. A breach in the right frontal bone, due to a car accident occurring the previous year, was considered the gateway for pneumococcal infection. Three days after admission, the girl developed drowsiness, altered speech and left hemiparesis. Brain MRI showed multiple T2-hyperintense bilateral lesions in the supratentorial white matter, and ADEM was diagnosed. Considering the underlying bacterial meningitis, intravenous immunoglobulins were preferred to steroid therapy, and the patient progressively recovered. However, due to recurrence of encephalopathic symptoms after 11 days, high-dose intravenous steroid therapy was performed. The neurological outcome was favourable, with complete regression of the white matter lesions after 4 months and absence of relapses over a follow-up period of 2 years.Conclusions: Occurrence of ADEM following pneumococcal meningitis is rare, and very few cases have been described in children. It should be suspected in case of persistence, recurrence or onset of new symptoms despite adequate antimicrobial treatment, relying on brain MRI for a thorough differential diagnosis. High level of surveillance is mandatory in patients with predisposing factors to invasive pneumococcal disease. In some cases, acute demyelination can occur few days after the onset of meningitis; pathogenetic mechanisms are not yet fully clarified and the choice of the correct therapeutic approach can be challenging.


Blood ◽  
2012 ◽  
Vol 120 (21) ◽  
pp. 5162-5162
Author(s):  
Mercedes Gasior ◽  
Hasan Ahmad ◽  
Stephen M. Hart ◽  
Christopher J McNamara

Abstract Abstract 5162 Pyrimethamine (Pyr) is a folate antagonist with a variety of indications. We report on the inadvertent poisoning of patients with Pyr who underwent bone marrow (BM) biopsy. There were 17 patients (median age 54); the most common presentation was gastrointestinal bleeding and pancytopenia. In January, 2012, hundreds of patients suffering from cardiac conditions were inadvertently poisoned with high dose Pyr at Punjab Institute for Cardiology in Lahore, Pakistan. There were more than 130 fatalities. A batch of isosorbide mononitrate tablets (Isotab, 20 mg) was contaminated with Pyr 50 mg. Patients estimated to have received contaminated drug for 14–21 days (cumulative dosage 2–3 grams). Patients presented with gastrointestinal bleeding, epistaxis, gum bleeding and subconjuntival ecchymosis, 5 with skin darkening, 1 with abdominal pain and vomiting, 4 had infectious complications (2 pneumonias, 2 febrile neutropenias); 1 died due to underlying cardiac disease. Laboratory analysis demonstrated (mean blood counts at admission): haemoglobin 113 g/L (61–154), white blood cells 2. 55 × 109/L (0. 7–7. 6), platelets 33 × 109/L(4–128). Clinical data provided by Jinnah and Services Hospital, Lahore, Pakistan. BM aspirates reviewed in haematology laboratory, Royal Free Hospital, London. BM samples taken in Pakistan before starting FA, within 2 weeks of stopping Pyr (stained with Romanowsky stain). Blood film, nor data on mean corpuscular volume (MCV) nor BM trephine available. All 17 had normal or hypercellular BM with severe megaloblastosis. Mean myeloid-erythroid ratio 4:1 (14. 7:1–1. 6:1). Severe megaloblastic change, giant metamyelocytes and abnormally lobulated mature granulocytes, 13 of 17 samples were left-shifted, with mild to moderate toxic change in 9. Erythroid lineage was not assessed in 5 due to quality of samples, 13 with marked nuclear:cytoplasmic dysynchrony and moderately severe dysplastic changes: ragged cytoplasm in 13, cytoplasmic bridging in 6, binucleate forms in 6, poor haemoglobinization in 3. Thrombopoiesis adequately assessed in 7, megaloblastic megakaryocytes in 2. High macrophage activity in 1 normocellular BM. Eosinophil count >5% in 6 cases. Following recognition of the cause, count recovery was prompt following discontinuation of Pyr and admistration of folinic acid (FA), Mean time to recovery of blood counts after FA 3. 89 days (2–5), and in 6 patients returned to normal before FA supplementation. FA started approximately 7 days after BM biopsy (mean time: 6, 5 days (5–10)). Mean duration of admission 10 days (3–28), 14 needed transfusion of blood components. Notable wide varietry of presentations, symptoms, depth of cytopenias and time to recovery. Part of this may be due to total dose, individual compliance with medication and pre-existing folate stores. In our series absolute dose of Pyr caused megaloblastosis, in patient group not known to be at risk of folate depletion. BM failure and megaloblastosis in absence of identifiable cause should prompt consideration of folate antagonists poisoning. Pyr can cause BM toxicity even as sole agent, independent of co-administration of other folate antagonists. Pyr poisoning, should be suspected in patients with unexplained cytopenias with megaloblastosis. FA therapy results in rapid improvement and should be offered to all patients, initially via the intravenous route. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
pp. 135245852199307
Author(s):  
Agnieszka Machlańska ◽  
Grzegorz Helbig ◽  
Karolina Chromik ◽  
Magdalena Zapała ◽  
Bartosz Zwiernik ◽  
...  

Background: Hemophagocytic lymphohistiocytosis (HLH) is a rarely recognized hyperinflammatory condition of high death risk. Objective: The objective was to describe a case of HLH in a patient with multiple sclerosis (MS) treated with ocrelizumab Methods: Clinical observation, laboratory testing, and use of HLH-2004 criteria for HLH diagnosis. Results: A 32-year-old Caucasian female developed HLH during ocrelizumab treatment. She met six of the eight HLH criteria including fever, splenomegaly, cytopenia, hypertriglyceridemia and hypofibrinogenemia, high serum ferritin level, and low natural killer (NK) cells. Conclusion: HLH should be considered in the differential diagnosis in MS patients displaying a fever and malaise syndrome following administration of ocrelizumab.


Sign in / Sign up

Export Citation Format

Share Document